Pareto Securities' Healthcare Conference: BioInvent has recently optimized its pipeline to focus on two key programs - BI-1808, the anti-TNFR2 antibody, and BI-1206, an FcγRIIB inhibitor

CEO Martin Welschof walks us through these two programs, which both target liquid and solid tumors. BI-1808 recently had data at EHA and will have solid tumor data later this year, while 2026 will be data rich for BI-1206.